Home/Filings/4/0001213900-17-002501
4//SEC Filing

Actinium Pharmaceuticals, Inc. 4

Accession 0001213900-17-002501

$ATNMCIK 0001388320operating

Filed

Mar 15, 8:00 PM ET

Accepted

Mar 16, 6:18 PM ET

Size

5.5 KB

Accession

0001213900-17-002501

Insider Transaction Report

Form 4
Period: 2017-03-14
DAVE KAUSHIK J
DirectorPresident and CEO
Transactions
  • Award

    Options to purchase common stock

    2017-03-14$1.39/sh+250,000$347,500250,000 total
    Exercise: $1.39Exp: 2027-03-14Common Stock (250,000 underlying)
Footnotes (1)
  • [F1]Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options shall vest each month from the date of grant. In addition, 100,000 options are subject to cancellation based on the obtainment of certain milestones.

Issuer

Actinium Pharmaceuticals, Inc.

CIK 0001388320

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001388320

Filing Metadata

Form type
4
Filed
Mar 15, 8:00 PM ET
Accepted
Mar 16, 6:18 PM ET
Size
5.5 KB